Interim results are promising from on ongoing phase 1 clinical trial testing an allogeneic or “off-the-shelf” chimeric antigen receptor Tcell (CAR T) therapy for patients with multiple myeloma who have not responded to existing treatments or who have relapsed.
A cancer vaccine that had little success in clinical trials for patients with advanced tumors could potentially have efficacy if administered earlier in the treatment cycle, according to a study from Vanderbilt researchers.
Jennifer Lewis, MD, MPH, and Lucy Spalluto, MD, MPH, are the recipients of the 2024 VAQS Team Award for work they began in 2017.
The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.
Cathy Eng, MD (Hematology and Oncology), is corresponding author of a paper published last week in The Lancet that provides an overview on treatment advances, clinical trials, incidence trends and ongoing challenges related to colorectal cancer, the third most diagnosed cancer in the world.
A prospective cohort of veterans including those with military toxic exposures, such as burn pits, will be screened annually with low-dose chest CT to detect lung cancer and other disease early.
Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best.
While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML.
Vanderbilt researchers, including Hematology and Oncology Drs. Justin Balko, Brian Lehmann and Vandana Abramson, have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has funded an ambitious initiative to overcome one of the most perplexing and frustrating mysteries of cancer treatment — how to prevent drug resistance. The three-year grant was awarded to Hematology and Oncology Dr. Ben Ho Park and Biochemistry Dr. Houra Merrikh.
